There’s no going “back to normal.”
My longtime readers already know this, but COVID-19 has changed our world permanently.
We can easily identify the obvious changes. There are more remote working options. Online grocery delivery is being quickly adopted. And, going forward, industries will have to rethink every major conference and public gathering.
But there are also less obvious changes taking place…
Breakthroughs in one technology sector that were five to ten years away are now happening on a monthly or weekly basis.
Which technology sector am I referring to? Biotechnology.
We’re at the start of a multiyear bull market in biotech. The pandemic has opened the doors for radically new approaches to vaccines and therapies, many of which were not taken seriously before.
It’s going to help us cure diseases at a pace previously unseen.
And for investors, it presents a once-in-a-generation opportunity to create enormous wealth.
The Rise of Biotech
When we picture biotechnology, I imagine 99% of us think of scientists in white lab coats fiddling with test tubes and peering under microscopes.
But the story is far more interesting. As I like to tell readers, biotech is much more “tech” than “bio” these days.
Today, the biotechnology industry is using big data, machine learning, and artificial intelligence to make breakthroughs that – even just a few years ago – would have seemed impossible.
Consider just one example…
Back in March, an early stage biotech firm AbCellera did something that many people thought was impossible.
AbCellera received a blood sample from a patient who had recovered from COVID-19. The company used artificial intelligence (AI) to screen more than five million immune cells in that sample. And it identified about 500 antibodies that helped the patient fight off the virus.
Identifying these antibodies could be the key to treating COVID-19. AbCellera used this as a starting point to create an antibody therapy to potentially cure COVID-19.
Historically, this process would have taken years to accomplish. So how long did it take AbCellera? Just 11 days. Beyond incredible.
And the industry took notice…
Pharmaceutical giant Eli Lilly rushed to partner with AbCellera. They worked on a treatment using these antibodies.
And in June, AbCellera sent its COVID-19 antibody therapy to clinical trials. It was the first company to do so.
If these clinical trials go well, the company could receive emergency use authorization (EUA) from the Food and Drug Administration (FDA). That will allow AbCellera to offer its therapy to the public in time for autumn.
That’s important because we will likely see another wave of COVID-19 cases when the weather gets cool and dry again.
Think about this for a minute. An early stage biotech took blood samples and identified COVID-19 antibodies. It then developed a therapy and launched clinical trials. And it did all this in four months. Until just recently, this process would have taken several years.
Make no mistake, this is revolutionary work.
In all my years as an analyst, I’ve never seen this type of speed from the biotech industry. And it’s thanks in large part to COVID-19. The virus has lit a fire under this overlooked industry.
But investors are now starting to notice…
Money Is Flooding Into Biotech
Suddenly, the world has woken up to the potential of biotechnology.
Every venture capitalist and private equity house has realized how powerful these technologies are and how quickly biotech can move. We’re going to see an acceleration in biotech investment, early stage companies, and IPOs (initial public offerings) as a result.
In fact, we’re already seeing that.
58% of all traditional IPOs this year have been biotechnology companies. And collectively, these companies have raised nearly $10 billion for drug development.
The 2020s will be the decade of biotech. This will be the first decade in which biotechnology companies truly harness the power of Moore’s Law and demonstrate exponential growth.
For us as investors, we need to be paying attention.
We can think of it this way…
In early 2017, cryptocurrencies were a mostly unknown, niche asset. But then the cryptocurrency space went on an unprecedented bull run before its painful correction in 2018. Bitcoin alone rose over 2,000% in 2017.
And I believe investors’ awareness and engagement in early stage biotech companies will rival that of the last crypto bull market.
But unlike cryptocurrencies – many of which were backed by nothing – early stage biotech is supported by very real, world-changing technology. The returns we will see from quality biotech companies will create lasting, generational wealth.
We are at the very beginning of a years-long biotech bull market. Breakthroughs will continue to happen. Diseases – previously thought untreatable – will be cured. And, yes, fortunes will be made.
We are entering a golden age of biotechnology. It’s happening right now.
Editor's Note: Our Top Biotech Pick…
They're Calling This “The Perfect $6 Stock”
What would the “perfect stock” look like to you?
If you wanted to place one trade and retire a millionaire, what would you look for in a single stock?
- Would it have the world’s most elite investors behind it?
Investors like the world’s richest man, Jeff Bezos…or billionaire and legendary investor, Peter Thiel…
- Would it have (proven) clinical trials of a technology so disruptive that it could save millions of lives?
- Would it have patented (Patent # ##,###,### ) technology that could monopolize a $8.18 trillion healthcare sector?
- Would it have stock shares trading at a dirt cheap price of $6?
- Would it have an incoming announcement that could start a historic market run like nothing we’ve ever witnessed before?
Well, what if I told you this exact stock exists and I have all the details waiting for you.
Would you be interested in learning how you could grab a 10,343% return on this historic stock?
All you need to do is click here for the details.